home / stock / gnpx / gnpx news

GNPX News and Press, Genprex Inc. From 12/22/20

Stock Information
Company Name: Genprex Inc.
Stock Symbol: GNPX
Market: NASDAQ
Website: genprex.com
Menu
GNPX GNPX Quote GNPX Short GNPX News GNPX Articles GNPX Message Board
Get GNPX Alerts

News, Short Squeeze, Breakout and More Instantly...
GNPX - Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA(TM) Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer

Major Manufacturing Milestone Positions the Company for Success In the Lung Cancer Therapeutics Market, expected to grow to $26.3 Billion by 2023 Achievement Highlighted by Important Process Improvements and Significantly Improved Economies of Scale Genprex, Inc. ...
GNPX - Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy

Successful Completion of Engineering Batch with Transfer from Research Institution to Commercial Contract Development and Manufacturing Organizations with Clinical Production Underway Manufacturing Technology Transfer Marks Major Company Milestone Genprex, Inc. (...

GNPX - Genprex to Present at the Benzinga Global Small Cap Conference on December 8

Presentation to Highlight the Company’s Recent Progress on its Upcoming Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene thera...

GNPX - Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Acclaim-1 trial combines REQORSA™ immunogene therapy drug with AstraZeneca’s Tagrisso® Company expects to recruit approximately 10 sites across the United States Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: ...
GNPX - Genprex to Participate in Panel at Life Sciences Summit on November 17

Thomas Gallagher, Senior VP of Intellectual Property and Licensing to provide insight into IP best practices to early-stage companies Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused...

GNPX - Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD

Inventor of the Company’s licensed diabetes gene therapy technology to provide leadership, strategy for diabetes program Dr. Gittes was recipient of a $2.59 million grant from the National Institutes of Health (“NIH”) National Institute of Diabetes and...

GNPX - Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer

New branding will support upcoming combination clinical trials, including the Company’s trial combining REQORSA™ immunogene therapy drug with AstraZeneca’s Tagrisso ® , which received FDA Fast Track Designation earlier in 2020 Genprex, Inc. ...
GNPX - Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA(TM) for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer

Approval of new name marks important branding milestone and aligns with the program’s overall progress REQORSA immunogene therapy uses the company’s unique, proprietary ONCOPREX™ nanoparticle delivery system to deliver cancer-fighting genes FDA gra...

GNPX - Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing

Promotion follows the Company’s achievement of key manufacturing milestones to support upcoming clinical trials Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing ...

GNPX - Genprex (GNPX) Investor Presentation - Slideshow

The following slide deck was published by Genprex, Inc. in conjunction with this event. For further details see: Genprex (GNPX) Investor Presentation - Slideshow

Previous 10 Next 10